RxDoctor Payments Data

Orville Cerna, MD

Internal Medicine · Pecos, TXNPI 1376554709

Payments from drug & device makers

$420in general payments, 2019–2025

Across 25 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$141
  • Johnson & Johnson$93
  • Novo Nordisk$40
  • GSK$35
  • Pfizer$33
  • Vifor Pharma, Inc.$21
  • plus $57 from 4 others

What the payments were for

  • Food & beverage$420100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$420 in reported general payments places this provider in the 55th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$11,755
Medicare patients
56
Services billed
122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide189$225,244
FarxigaDapagliflozin Propanediol205$146,291
EliquisApixaban165$79,358
JanuviaSitagliptin Phosphate59$59,551
MounjaroTirzepatide47$53,773
JardianceEmpagliflozin62$50,157
TrulicityDulaglutide29$34,329
TradjentaLinagliptin45$33,229
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$26,770
Breo ElliptaFluticasone/Vilanterol53$22,039
LinzessLinaclotide20$19,665
Janumet XrSitagliptin Phos/Metformin Hcl18$17,652
UbrelvyUbrogepant16$16,626
JanumetSitagliptin Phos/Metformin Hcl13$15,977
MultaqDronedarone Hcl25$15,286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$40$225,244189 claims
AstraZenecaFarxiga$14$146,291205 claims
MerckJanuvia, Janumet Xr, Janumet$13$93,17990 claims
Lilly USA, LLCMounjaro, Trulicity$141$88,10276 claims
PfizerEliquis$33$79,358165 claims
GSKTrelegy Ellipta, Breo Ellipta$35$48,81094 claims
AbbVieLinzess, Ubrelvy$15$36,29136 claims
Johnson & JohnsonXarelto$93$10,90714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Pecos

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →